DM
ITCI

Deerfield Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Deerfield Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,910
Closed -$208K – 437
2023
Q4 		$208K Buy
+2,910
New +$167K ﹤0.01% 170
2023
Q2 		– Sell
-734,000
Closed -$39.7M – 112
2023
Q1 		$39.7M Buy
+734,000
New +$35.5M 0.89% 35
2017
Q4 		– Sell
-118,116
Closed -$1.86M – 105
2017
Q3 		$1.86M Buy
+118,116
New +$1.73M 0.08% 89
2014
Q2 		– Sell
-171,437
Closed -$3.12M – 149
2014
Q1 		$3.12M Buy
+171,437
New +$3.09M 0.13% 102

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Deerfield Management's ITCI Position: Q1 2024 in Review

Deerfield Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2024, closing a stake of 2,910 shares — an estimated $208K sold.

Deerfield Management first reported a position in ITCI in Q1 2014 and held it in 4 quarters. The position peaked at $39.7M in Q1 2023. 345 funds tracked by Wall St. Rank hold ITCI as of Q1 2024.

  • Deerfield Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2024 after selling out during the quarter.
  • Deerfield Management sold 2,910 Intra-Cellular Therapies Inc. shares in Q1 2024, an estimated $208K.
  • Deerfield Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2014 and held it in 4 quarters.
  • Deerfield Management's Intra-Cellular Therapies Inc. position peaked at $39.7M in Q1 2023.
  • 345 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2024.

Based on Deerfield Management's 13F filing for Q1 2024, filed 15 May 2024.